Showing posts with label Harvard. Show all posts
Showing posts with label Harvard. Show all posts

Monday, October 24, 2016

3D Bioprinting to Engineer Human Tissue: Wyss Institute's David Kolesky at Biotech Week Boston

The medical 3D printing market is expected to reach $983.2 million by the year 2020. What is the difference between medical and other 3D printing? Well to explain very simply, I will use a quote from Hod Lipson from ASME.org (Lipson is the author of  Fabricated: The New World of 3D Printing): “Unlike traditional 3D printing of plastics and metal where after you finish printing you have your part, with bioprinting it’s just the beginning. Even after you finish printing there is a long road ahead. You have to incubate the part, simulate its environment – it’s much more complicated.”

This month I was lucky enough to hear David Kolesky from Harvard University’s Wyss Institute discuss his team’s latest work on 3D bioprinting. The idea that we are beginning to be able to print human tissue is mind-blowing, and to hear details from someone in the forefront of this work was awe-inspiring.

Human Tissue Engineering: Challenges and Solutions
David Kolesky is part of a team at Jennifer Lewis' Research Group at the Harvard John A. Paulson School for Engineering and Applied Sciences (SEAS) and the Wyss Institute for Biologically Inspired Engineering at Harvard University who is working on engineering human tissue. In his talk at Biotech Week Boston on October 6, Kolesky focused on the team's work with engineering kidney tissue in particular. He described his team’s focus and some of their challenges: “(A human) kidney has a million nephrons, within the nephron we’re focused on the proximal tubule” and “(human) tissue is extremely difficult to mimic, because (of its) hierarchical structures that have a composite nature.” (You can see the tubule below, courtesy Wyss Institute.)


Stem-Cell Laden ‘Ink’ Becomes Living Tissue
Kolesky told the story of exactly how he was using 3D printing, specifically “bioprinting” to solve the challenges of vascularization. To someone not well versed in the latest discoveries it was fairly astounding – especially when he elucidated the use of “stem-cell laden ‘ink’ to build fully vascularized human tissue”. The materials they’re using are almost as fascinating at the engineered tissue: a hydrogel, which becomes “liquid when cooled” is the substance Kolesky and the Wyss Institute is using to make the bioprinting happen. With the methods he’s using, they are able to “keep these vascular networks perfusable for up to 45 days”. Their 3D printed proximal tubules actually contain living human cells and mimic many biological functions of nephrons.

How do they do that? Once the tubules are printed, they pump living kidney cells into them. After several days in the tubules the cells begin to function like the ones in our bodies. Cells in the tubules are “trained” by the chemistry of their environment to become and behave exactly like native kidney cells.

Researchers Can Now Study Real-Time Damage To Tubules
There are 60,000 people on a national waiting list for kidneys, and the CDC says that 1 in 10 American adults, more than 20 million people, have some level of chronic kidney disease. There is an urgent need for science to advance this research. The Wyss Institute is not only at the forefront of bringing us closer being able to engineer human kidneys in the future; with the current research researchers will actually be able to induce damage on these bioengineered tubules as if they were the real thing to study effects of drugs or toxins.

We Want a Synergistic Relationship with Biology
Kolesky closed his talk with the quote: ”We want a synergistic relationship with biology.” In fact Wyss Institute's Mission Statement is: "The Wyss Institute seeks to transform engineering, medicine and the environment by creating new materials and devices using Nature’s design principles".

Their team's paper:”Bioprinting of 3D Convoluted Renal Proximal Tubules on Perfusable Chips” was published in Nature Scientific Reports several days after Biotech Week Boston and gives more detail on Kolesky’s research. You can read the paper here.

Interested in hearing more about innovations in the intersection of bioengineering and medicine? Download our report here. And don't forget to follow Biotech Week Boston on Twitter for news on innovation in biotech and medicine. Each year passionate scientists and innovators converge on Boston to share ground breaking data, research and ideas - don't miss our next event in September 2017!





Share this article with your social network, just click below to share now!


Thursday, September 1, 2016

New Report: Convergence in Boston: How multidisciplinary R&D is driving bench-to-bedside breakthroughs

The area in and around Boston, Massachusetts is as dense with world-renowned scientific experts as anywhere on earth. Here, in an area a little larger than one square mile, researchers from Harvard University, Massachusetts Institute of Technology (MIT), and a multitude of biotechs and Big Pharmas are driving the evolution of the technology and business of science. In doing so, research teams are increasingly looking to share data, research, and ideas.

Download the Report

Collaboration has always been key to science, but, as researchers have taken on ever-more complex projects, the need to work with people from different disciplines, backgrounds, and organizations has increased. Such collaborations run counter to the secretive, ego-driven, or financially-motivated sides of science, but have nonetheless taken root, even in for-profit fields, as organizations have realized the value of expanding the breadth of their internal expertise while looking outside of their walls for collaborators. We at Biotech Week Boston are excited by the possibilities that this new era of collaboration can bring to biotech. We’ve asked writer Nick Paul Taylor (Nature, Fierce Biotech, Regulatory Focus) to report on several innovators who are contributing to this convergence of disciplines and ideas here in Boston.

In this report, Nick looks at three people: "who have embraced the collaborative, multidisciplinary ethos and, in doing so, have influenced science, business, and the lives of patients to a far-greater degree than would have been possible through an isolationist approach. Their goals are diverse. One is working to improve drug availability in low and middle-income countries through the advance of biomanufacturing. Another is looking to nature for answers to biomedical problems that blight the lives of patients. Our third is coordinating a global campaign to unlock the secrets of the genome."

Nick continues: "What links the three researchers is not the type of science they do, but the way they do it. Each is an example of what scientists, particularly in hotspots such as Boston, can achieve when they are open to the sharing of data, research, and ideas."

We hope you enjoy Nick’s in-depth report. We are proud to say that all three innovators featured in this report will be speaking at Biotech Week Boston this October 2016. You can catch up with Jeffrey Karp’s newest discoveries and research at Biotech Week Boston's Cell and Gene Therapy Bioprocessing and Commercialization event. Jeffrey's talk is entitled "MSCs on steroids". Stacy Springs will be on a panel entitled "Industry-Academia Collaboration in Translational Research and Biomanufacturing of Next Generation Biologics at the Bioprocess International Conference and Exhibition. And Kristin Ardlie will discuss discuss GTEx Data and Analysis at Biorepositories and Sample Management.

We invite you to download “Convergence in Boston: How multidisciplinary R&D is driving bench-to-bedside breakthroughs.” The report is free and no email address or registration is required - so go ahead and share the link!



Share this article with your social network, just click below to share now!


Tuesday, August 30, 2016

How the Broad Institute’s GTEx uses a multidisciplinary approach to translate research into medicine

MIT’s new report “Convergence: The Future of Health” states: “Convergence comes as a result of the sharing of methods and ideas by chemists, physicists, computer scientists, engineers, mathematicians, and life scientists across multiple fields and industries. It is the integration of insights and approaches from historically distinct scientific and technological disciplines. Convergence is a broad effort across the sciences that will play a crucial role in many fields of endeavor. As noted above it needs to be applied to help solve many of the world’s grand challenges.”

We’ve asked writer Nick Paul Taylor (Nature, Fierce Biotech) to research several innovators who are contributing to a multidisciplinary convergence right here in Boston. The paper is entitled: "Convergence in Boston: How Multidisciplinary R&D is driving bench to bedside breakthroughs".

Kristin Ardlie


Nick reports on what the Broad Institute, specifically in their Genotype-Tissue Expression (GTEx) project, is contributing to understanding disease in their work with genomics. Genomics has, since its earliest days, been a multidisciplinary field. The sequencing, analyzing, and contextualizing of genomes necessitates the input of experts from a broad range of backgrounds. Nick spoke with Kristin Ardlie, Ph.D., the Senior Research Scientist, Director of GTEx at the Broad Institute of MIT and Harvard. The GTEx project started in 2010 “with the goal of creating a comprehensive atlas and open database of gene expression and gene regulation across human tissues.” Nick explores Kristin Ardlie and the Broad Institute’s work to discover how and why the field of genomics needs to draw on a diversity of skills and disciplines to handle the myriad of tasks involved in understanding inherited susceptibility to disease.

We hope you enjoy Nick’s in-depth report. You can catch up with Kristin Ardlie and The Broad Institute’s Genotype-Tissue Expression projects newest research at Biotech Week Boston's Biorepositories and Sample Management event this October. Kristin will discuss GTEx Data and Analysis.





Share this article with your social network, just click below to share now!